Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How KLRA compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 100.0% | +129.4 pp | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | 99.4% | -0.6 pp | — |
| LTM Jun 2026 | 92.1% | -7.9 pp | -0.3 pp | |
| FY2025 | 0.7% | — | -99.4 pp | |
| LTM Mar 2026 | -41519.4% | -41619.4 pp | +0.0 pp | |
KLRAKailera Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding KLRA) | 92.1% | -4.2 pp | -0.3 pp | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.